API Pharmaceutical Raw Material 56180-94-0 99% Acarbose powder for Treating Diabetes

Acarbose More Info

Acarbose (CAS: 56180-94-0) is an alpha-glucosidase inhibitor derived from microbial fermentation, primarily used in the management of blood sugar levels. It was first isolated from Actinoplanes bacteria and later developed as an oral antidiabetic medication. Unlike insulin or sulfonylureas, Acarbose works by delaying carbohydrate digestion in the small intestine, thereby reducing postprandial glucose spikes. It is classified as a competitive enzyme inhibitor and is widely recognized in pharmacopeias such as the USP, EP, and JP. Due to its mechanism of action, it is particularly effective in managing type 2 diabetes and related metabolic disorders.

Primary Applications

Acarbose is predominantly used in the pharmaceutical industry as an active pharmaceutical ingredient (API) in antidiabetic drugs. It is formulated into tablets (e.g., Glucobay, Precose) for diabetes treatment, often in combination with other hypoglycemic agents like metformin. Beyond human medicine, it has been explored in veterinary applications for managing insulin resistance in animals. Additionally, research studies investigate its potential in pre-diabetes intervention and metabolic syndrome due to its ability to modulate gut microbiota and improve glucose tolerance.

Market and Industry Demand

The global market for Acarbose is driven by the rising prevalence of type 2 diabetes, particularly in aging populations and emerging economies like China and India. Major pharmaceutical manufacturers, including Bayer and generic drug producers, dominate its supply chain. Regulatory approvals from agencies such as the FDA, EMA, and NMPA ensure its widespread clinical use. The API is also supplied to compounding pharmacies and contract manufacturers for customized diabetic care solutions. With increasing focus on personalized diabetes management, demand for Acarbose remains stable, though competition from newer drug classes (e.g., SGLT2 inhibitors) influences market dynamics.

Key Considerations

When handling Acarbose, compliance with GMP standards is critical to ensure purity and efficacy. Storage conditions (typically 2–8°C for long-term stability) must be strictly maintained to prevent degradation. Clinically, gastrointestinal side effects (e.g., flatulence, diarrhea) are common and require patient monitoring. Manufacturers must also validate analytical methods (HPLC, dissolution testing) to meet pharmacopeial requirements. For export, documentation such as EDMF/ASMF, GMP certificates, and stability data are essential, particularly for regulated markets like the EU and US. Environmental and workplace safety protocols should address dust control due to its fine powder form.